PRI's Focus on Health Care

View this email in your browser ([link removed])
[link removed]
Democrats Remain Jealous Of Britain’s Healthcare Catastrophe

Forbes | Sally C. Pipes
July 6, 2020

Of course, “elective” can be a subjective term. Many American patients are putting off treatment for cancer, cardiovascular diseases, and other chronic conditions in order to avoid potential exposure to the virus and do their part to preserve healthcare resources for those afflicted with COVID-19. In places that have relaxed stay-at-home orders, people are starting to head back to the clinic to get the care they need.
Read more. . . ([link removed])

Dr. Henry Miller and John Batchelor Review FDA COVID-19 Guidelines
The John Batchelor Show | Henry Miller, M.S., M.D.
July 1, 2020

PRI’s Dr. Henry Miller joins the John Batchelor Show to review the latest developments with the vaccine guidelines and the FDA. The FDA recently testified before Congress that they will have complicated guidelines for a potential COVID-19 vaccine. Miller mentioned that the FDA guidelines are reassuring as it indicates that future vaccines will be vetted like any other vaccine evaluation (pre-critical data, manufacturing and controls, and clinical data).

Listen here. . . ([link removed])

Coronavirus drug cost – Ignore critics. Here’s why the price is right
Fox News | Sally C. Pipes
July 5, 2020

Given the drug’s benefits, and the potential savings for the health care system, Gilead’s proposed $3,100 price is eminently fair. The Institute for Clinical and Economic Review – a group that sets cost-effectiveness thresholds for new drugs and is generally critical of the pharmaceutical industry – admitted that Gilead “made a responsible pricing decision.” ICER concluded that Gilead could reasonably charge up to $5,080 for a 10-day course of remdesivir.
Read more. . . ([link removed])
[link removed]
How Medicines are Sold, Part 2 ([link removed])
PRI | Drug Pricing Video Series
July 2, 2020
In the latest drug pricing video, the Professor and Pete learn how infusion drugs – drugs that you have to go to a doctor’s office, clinic or hospital to take – are sold and how the complex pricing environment encourages the use of these higher cost drugs rather than lower cost alternatives like biosimilars.

Click here to watch. . . ([link removed])

============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2020 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
101 Montgomery Street, Suite 1300, San Francisco, CA 94104

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.